Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2011 December;63(6) > Minerva Ginecologica 2011 December;63(6):495-504



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 2011 December;63(6):495-504


Clinical function of estrogen receptors in endometrial cancer

Caringella A. M., Di Naro E., Loverro G.

Seconda Unità Operativa di Ginecologia e Ostetricia, Dipartimento di Ginecologia, Ostetricia e Neonatologia, Università degli Studi di Bari, Bari, Italia

Approximately 70-80% of endometrial carcinomas, type I carcinomas, are associated with endometrial hyperplasia, hyperestrogenism, and expression of estrogen receptor (ER). The aim of this review was to clarify the role of ER in endometrial diseases carcinoma. The estrogens exert their effect via two estrogen receptor: α and β. The ERs modulate transcriptional process by binding directly to the estrogen response elements (ERE) located in the target gene, or in non classical mode through protein-protein tethering with other transcription factors. There are also orphan receptors (their natural ligands have not been identified). Among this group, estrogen receptor-related receptors (ERRs) were identified by their sequences similar to those of ERs. Since the ERRs have shown a high similarity in DNA binding domain with ERs can interfere with estrogen signalling strengthening the hypothesis of an estrogen-ER-ERR crosstalk. Recently, the ERs and estrogen enzymes emerge as pharmacological targets in different disorders, as well as ERRs, and they may represent the reliable biomarkers in endometrial disease.

language: Italian


top of page